Top Markets
#1 Islamic Coin Islamic Coin +154.47%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.66%
#4 BOOK OF MEME BOOK OF MEME +14.50%
#5 Starpower Starpower +13.44%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.16%
#7 MarsCoin MarsCoin +11.40%
#8 Venom Venom +11.38%
#9 Lighter Lighter +10.73%
#10 Nockchain Nockchain +10.69%
Coin of the day
Islamic Coin Islamic Coin
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Biocartis Group N.V. Biocartis Group N.V.

Biocartis Group N.V.

BCART
Kedudukan dalam Saham #27531
Biocartis Group NV is a molecular diagnostics firm dedicated to improving... Biocartis Group NV is a molecular diagnostics firm dedicated to improving clinical care. Its innovative diagnostic solutions primarily serve the oncology sector, benefiting patients, medical professionals, insurers, and the broader healthcare ecosystem. The company's cornerstone is its exclusive Idylla molecular diagnostics platform, a sophisticated real-time polymerase chain reaction (PCR) system. This technology delivers crucial molecular data, aiding in the selection of appropriate treatments and the continuous monitoring of patient progress. Biocartis offers a range of diagnostic tests via the Idylla system, including mutation analysis for BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Additionally, it provides Idylla panels for SARS-CoV-2/Flu/RSV, standalone SARS-CoV-2 tests, and the rapid host-response assessment, SeptiCyte RAPID. For research purposes, the company supplies various mutation assays, such as those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis has entered into strategic partnerships to broaden its impact. One such collaboration is with Amgen, focusing on evaluating Idylla RAS testing to enable swift, decentralized diagnostics and enhance the accessibility of RAS biomarker data through the Idylla platform and its associated RAS tests. Another key alliance is with Bristol-Myers Squibb Company, centered on the registration and application of the Idylla MSI test within the field of immuno-oncology treatments. Furthermore, a licensing, development, and commercialization agreement with GeneproDx is in place for the creation of the innovative ThyroidPrint genomic test, to be integrated onto the Idylla platform. Established in 2007, Biocartis maintains its corporate headquarters in Mechelen, Belgium.
Harga Saham
$0.343985
Disegerakkan terakhir: 2024-07-23
Modal Pasaran
$32.31M
Perubahan (1 hari)
11.88%
Perubahan (1 tahun)
0.00%
Negara
BE
Perdagangan Biocartis Group N.V. (BCART)

Kategori

Healthcare
Margin Operasi untuk Biocartis Group N.V. (BCART)
Margin Operasi pada 2026 TTM: 0.00%
Menurut laporan kewangan dan harga saham terkini Biocartis Group N.V., margin operasi semasa (TTM) ialah 0.00%. Pada akhir 2026, margin operasi syarikat ialah 0.00%.
Sejarah Margin Operasi untuk Biocartis Group N.V. dari 2026 hingga 2026
Margin Operasi pada akhir setiap tahun
Tahun Margin Operasi Ubah
Tidak cukup data untuk tarikh yang disediakan.
Margin Operasi untuk syarikat serupa atau pesaing
Syarikat Margin Operasi Perbezaan Margin Operasi Negara
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
17.69% -
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
20.42% -
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
0.00% -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
-10.70% -
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
32.03% -
US
Apakah Margin Operasi sesebuah syarikat?
Margin Operasi ialah penunjuk utama untuk menilai keuntungan sesebuah syarikat. Margin Operasi yang lebih tinggi lazimnya lebih baik kerana menunjukkan bahawa syarikat mampu menjual produk atau perkhidmatannya dengan harga yang jauh lebih tinggi daripada kos pengeluarannya. Ia dikira dengan membahagikan keuntungan syarikat dengan hasilnya.